About Olfactory receptor 1E2
Olfactory receptor 1E2 (OR1E2) is a protein
from Homo sapiens identified by UniProt accession
P47887, 323 residues long.
MolForge cross-references it against 0 known binders and
49 disease associations.
Target properties
| Protein name | Olfactory receptor 1E2 |
|---|
| UniProt accession | P47887 |
|---|
| Gene | OR1E2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 323 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (49)
Diseases linked to this target (Open Targets).
- hepatocellular carcinoma · score 0.18
- Lynch syndrome · score 0.08
- colorectal cancer, susceptibility to, 3 · score 0.06
- inflammatory bowel disease · score 0.06
- Testicular regression syndrome · score 0.06
- Hirschsprung disease · score 0.06
- Meckel's diverticulum · score 0.06
- familial adenomatous polyposis 2 · score 0.05
- AXIN2-related attenuated familial adenomatous polyposis · score 0.05
- 46,XY complete gonadal dysgenesis · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P47887-F1 | alphafold | PREDICTED | 85.87 | — |
Amino-acid sequence (323 residues)
MMGQNQTSIS DFLLLGLPIQ PEQQNLCYAL FLAMYLTTLL GNLLIIVLIR LDSHLHTPVY LFLSNLSFSD LCFSSVTMPK LLQNMQNQDP SIPYADCLTQ MYFFLYFSDL ESFLLVAMAY DRYVAICFPM HYTAICFLLH YTAIMSPMLC LSVVALSWVL TTFHAMLHTL LMARLCFCAD NVIPHFFCDM SALLKLACSD TRVNEWVIFI MGGLILVIPF LLILGSYARI VSSILKVPSS KGICKAFSTC GSHLSVVSLF YGTVIGLYLC PSANSSTLKD TVMAMMYTVV TPMLTPFIYS LRNRDMKGAL ERVICKRKNP FLL
Explore Olfactory receptor 1E2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets